Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +34.90% | +20.20% | +17.26% | +149.35% | +84.95% |
| Gross Profit Growth | +38.57% | +22.13% | +6.70% | +153.44% | +69.13% |
| EBITDA Growth | +0.00% | +0.00% | -49.23% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | -133.32% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.37% | +2.80% | +2.32% | +2.22% | +2.83% |
| Weighted Average Shares Diluted Growth | +2.37% | +2.80% | +2.32% | +6.81% | +5.98% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +23.82% | +643.84% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +20.06% | +692.02% | +0.00% |
| Receivables Growth | +23.65% | +30.08% | +83.25% | +172.65% | +91.85% |
| Inventory Growth | -11.93% | -30.22% | -14.64% | -0.79% | +5.36% |
| Asset Growth | +10.71% | +10.18% | +13.88% | +15.38% | +17.13% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +607.21% | +1043.93% |
| Debt Growth | +2.27% | +1.41% | +1.16% | -52.00% | -53.40% |
| R&D Expense Growth | +10.30% | +1.58% | +10.02% | +32.44% | +24.00% |
| SG&A Expenses Growth | +49.07% | +13.83% | +30.16% | +45.74% | +10.17% |